You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

2068 Results
Document
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of advanced renal cell carcinoma (RCC), based on criteria
Dec 2024
Drug
Other Name(s): Lynparza®
Jan 2025
Document
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
May 2019

Pages